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EDITORIAL
Cardiac  resynchronization:  What’s  next?
Resynchronisation  cardiaque  :  quel  avenir  ?
Cardiac  resynchronization  therapy  (CRT)  is  one  of  the  major  therapeutic  advances  to  have
KEYWORDS
Cardiac
resynchronization
therapy;
taken  place  in  cardiology  over  the  past  decade.  The  beneﬁt  of  CRT  is  obtained  on  top  of
optimal  drug  treatment,  primarily  in  patients  with  left  ventricular  (LV)  dysfunction,  wide
QRS  and  severe  heart  failure  (NYHA  class  III  and  IV)  and,  more  recently,  with  moderate  heart
failure  (NYHA  class  II)  [1].  It  is  noteworthy  that  over  the  same  period  many  attempts  toHeart  failure;
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improve  outcome  have  been  performed  using  different  pharmacological  drugs,  but  without
real  success,  with  the  exception  of  ivabradine  and  eplerenone.
Even  after  15  years  of  CRT  many  questions  remain  to  be  answered.  One  such  question
relates  to  the  fact  that  despite  thousands  of  implantations  of  CRT  devices  worldwide,  the
proportion  of  patients  who  do  not  beneﬁt  from  CRT  —  the  so-called  the  non-responders  —
has  remained  unchanged.  The  rate  of  non-response,  according  to  the  deﬁnition  based  on
clinical  or  echocardiographic  criteria,  ranges  from  30  to  55%  [2],  which  is  unacceptably
high  for  an  invasive  and  costly  therapeutic  procedure.  We  have  to  recognize,  however,
that  not  all  patients  respond  to  drug  therapy  either,  but  the  issue  of  non-responders  to
pharmacological  therapy  tends  to  be  discussed  less  frequently.
To  reduce  the  rate  of  non-responders  to  CRT,  we  have  to  reﬁne  patient  selection.
Patients  who  will  not  respond  or  who  are  poor  responders  need  to  be  identiﬁed  and  elim-
inated  from  selection;  but  we  also  need  to  improve  the  pacing  modalities  and  optimize
the  programming  and  follow-up  of  these  fragile  patients,  and  use  the  haemodynamic  data
provided  by  these  devices.
For  patient  selection,  the  deﬁnition  of  ventricular  dyssynchrony  is  based  on  the  QRS
width  on  a  surface  ECG  — an  apparently  simple  but  probably  too  simplistic  criterion.  First
of  all,  we  have  to  recognize  that  there  is  no  standardization  when  measuring  QRS  dura-
tion.  An  interesting  study  showed  inter-  and  intraobserver  variability  in  the  measurement
of  QRS  duration,  and  hence  the  poor  reliability  of  this  variable  [3].  Data  from  randomized
controlled  trials  have  shown  consistently  that  the  magnitude  of  response  to  CRT  is  higher
in  patients  with  a  very  wide  QRS  (>  150  ms)  and/or  the  presence  of  left  bundle  branch  block
[2].  Current  European  guidelines,  updated  in  2010,  consider  only  the  QRS  duration  for  the
deﬁnition  of  ventricular  dyssynchrony,  with  different  cut-offs  according  to  the  severity
of  the  heart  failure  (120  ms  for  NYHA  class  III  or  IV  patients  and  150  ms  for  NYHA  class  II
patients),  but  without  any  consideration  for  the  type  of  conduction  disorder  (i.e.  LBBB  vs
non-LBBB)  [1].  New  European  guidelines  are  under  construction  and  should  consider  not
only  QRS  duration  but  also  the  absence  or  presence  of  LBBB  when  selecting  candidates
for  CRT.  Interestingly,  recent  guidelines  published  by  the  Heart  Failure  Society  of  Amer-
ica  integrate  the  type  of  ventricular  conduction  disorder  [4].  Despite  many  encouraging
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eports  from  single-centre  studies,  it  is  noteworthy  that
maging  techniques  are  not  implemented  in  the  guidelines  to
mprove  the  selection  of  patients.  This  statement  is  related
o  the  inconclusive  results  of  the  Predictors  of  Response
o  CRT  (PROSPECT)  trial,  but  we  can  expect  that  imaging
echniques  (not  only  echocardiography!)  with  new,  more
ensitive,  reproducible  and  less  operator-dependency  will
lay  an  important  role  in  the  selection  of  patients  for  CRT.
nother  important  criterion  is  the  nature  of  the  underlying
ardiomyopathy.  The  extent  of  myocardial  scarring  may  play
 role  and  be  associated  with  reduced  CRT  responsiveness.
ata  are  insufﬁcient  to  support  a  speciﬁc  recommendation,
ut  clinicians  should  weigh  the  risks  against  the  poten-
ial  beneﬁts  of  CRT  implantation  in  patients  with  extensive
yocardial  scar,  particularly  in  the  location  of  the  LV  lead
lacement.  Imaging  techniques  with  fusion  of  data  may  be
ery  helpful.  Finally,  the  presence  of  a  dysfunction  of  the
ight  ventricle  appears  to  be  an  important  predictive  factor
f  non-response  to  CRT,  suggesting  the  need  for  careful  eval-
ation  of  the  right  ventricle  in  the  selection  of  candidates
or  CRT.
The  position  of  the  LV  lead  may  have  an  important
mpact  on  the  clinical  and  echocardiographic  outcomes  of
RT  patients.  Classically,  the  recommended  LV  lead  location
s  the  lateral  or  postero-lateral  LV  wall-based  on  previous
aemodynamic  studies  [2].  However,  data  from  three  clini-
al  trials  showed  that  the  lateral  position  was  not  necessarily
ssociated  with  a  better  clinical  outcome  compared  with
osterior  or  anterior  positions  [5—7]. These  observations
einforce  the  need  for  individual  positioning  of  the  LV  lead
n  respect  of  the  pattern  of  ventricular  activation  and  the
resence  of  scar  and/or  ﬁbrosis.
Some  authors  have  suggested  that  providing  more  pacing
ites  in  the  right  or  left  ventricles  would  improve  the  correc-
ion  of  cardiac  dyssynchrony  and  thus  improve  response  to
RT.  In  an  acute  study  in  21  patients,  Yoshida  et  al.  showed
hat  triple-site  pacing  using  one  LV  lead  and  two  right  ven-
ricular  leads,  one  at  the  apex  and  one  at  the  right  outﬂow
ract,  signiﬁcantly  improved  LV  haemodynamics  compared
ith  conventional  biventricular  pacing  [8].  Another  triple
acing  site  conﬁguration  with  two  LV  leads  positioned  in  the
oronary  sinus  has  been  studied.  Mid-term  results  from  small
tudies  have  shown  promising  results  [9,10]. These  encour-
ging  results  have  to  be  conﬁrmed  by  further  randomized
rials  such  as  the  TRUST  CRT  (Triple-site  versus  standard
ardiac  resynchronization  therapy)  study,  conducted  in  de
ovo  CRT  patients  [9].  The  V3  trial,  designed  to  assess  the
otential  efﬁcacy  of  a  second  LV  lead  in  non-responders,  is
ngoing  [11].
Alternative  LV  pacing  modalities  to  the  coronary  sinus
oute  have  been  proposed,  especially  in  case  of  failure  of
V  lead  implantation  [2].  Epicardial  LV  pacing  using  a  mini-
nvasive  thoracotomy  or  thoracoscopy  can  be  performed.
nother  promising  approach  is  endocardial  biventricular
acing,  which  provides  a  more  physiological  electrical  acti-
ation  since  the  activation  originates  in  the  endocardium
nd  spreads  towards  the  epicardium.  Different  routes  have
een  proposed,  mainly  using  an  interatrial  septum  or
ransapical  routes.  A  recent  acute  study  based  on  the  mea-
urement  of  LV  dP/dt  reported  that  there  is  a  considerable
ntervariability  in  the  location  of  the  optimal  endocar-
ial  pacing  site,  suggesting  again  a  tailored,  individualized
i
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pproach  for  each  patient  [12]. However,  there  are  safety
ssues  to  consider  such  as  thromboembolism  or  infection  of
he  endocardial  pacing  lead  or  the  impact  of  the  mitral  valve
unctioning.  Further  studies  are  warranted  to  evaluate  the
afety  and  superiority  of  these  alternative  strategies  over
onventional  biventricular  pacing  in  the  future.
The  follow-up  of  patients  implanted  with  a  CRT  device
hould  focus  on  a  multidimensional  approach  to  maximize
linical  response  to  the  therapy.  This  includes  a systemati-
ally  executed  optimization  procedure  of  the  device  itself.
ecent  data  suggest  that  a  high  percentage  of  biventric-
lar  pacing  (>  92%)  is  mandatory  for  the  clinical  success
f  the  therapy  [2].  Basic  device  parameters  such  as  the
asal  pacing  rate,  the  upper  limit  rate  as  well  as  the  need
or  a  rate-responsive  function  have  to  be  carefully  eval-
ated  in  each  patient.  The  lack  of  optimization  of  the
trioventricular  (AV)  intervals  has  been  suggested  recently
s  an  important  cause  of  non-response  to  CRT  [6].  How-
ver,  the  Freedom  (Frequent  Optimization  Study  Using  the
uickOpt  Method)  and  SMART-AV  (SmartDelay  determined
V  optimization:  a  comparison  to  other  AV  delay  methods
sed  in  cardiac  resynchronization  therapy)  trials  comparing
EGN-based  algorithms  or  echo-based  AV  optimization  have
uggested  that  the  ‘out-of-the-box’  setting  (i.e.  the  default
arameters  ensuring  biventricular  pacing)  may  work  sufﬁ-
iently  [13,14]. However,  it  is  still  a  matter  of  debate  if
hese  studies  will  have  limitations  in  their  design,  pre-study
ssumption  and  power  calculations.  Current  CRT  devices
rovide  the  possibility  to  optimize  the  interventricular  (VV)
elay,  allowing  simultaneous  biventricular  pacing  or  sequen-
ial  pacing  with  different  degrees  of  VV  delays  or  VV
elays  preexcitation.  Up  to  now,  there  is  still  controversy
bout  whether  an  individual  AV/VV  optimization  protocol  is
ecessary  in  every  implanted  CRT  patient  or  only  for  non-
esponders.
Today,  cardiac  resynchronization  devices  record  and  pro-
ide  important  information  about  different  ‘haemodynamic’
arameters  [2].  We  may  have  easy  access  to  the  patient’s
ctivity,  their  night-time  and  daily  heart  rate,  and  heart  rate
ariability,  but  we  also  have  important  information  about
he  pulmonary  ﬂuid  status  via  the  transthoracic  impedance
r  the  respiratory  status  [2].  However,  the  reliability  of  the
onitoring  of  the  pulmonary  ﬂuid  status  remains  controver-
ial  with  the  current  technology  [2].  The  devices  also  provide
ata  about  the  occurrence  and  the  prevalence  of  atrial
nd  ventricular  arrhythmias  as  well  as  another  important
arameter,  the  percentage  of  biventricular  pacing.  In  non-
esponders,  knowledge  of  these  parameters  may  identify  the
ause  of  non-response  and  thus  the  most  appropriate  action
ecessary.  However,  to  be  more  efﬁcient,  knowledge  of  all
f  these  parameters  has  to  be  delivered  in  a  timely  man-
er  to  the  patient’s  physician.  The  development  of  remote
onitoring  improves  the  monitoring  of  the  device  but  also
rovides  information  about  the  status  of  the  patient.  With
his  technology,  information  on  body  weight  and  blood  pres-
ure  —  very  simple  but  important  factors  in  the  follow-up
f  heart  failure  patients  —  is  transmitted  to  the  physician.
ome  preliminary  data  are  encouraging  in  terms  of  improv-
ng  follow-up  of  these  patients  [15,16].  New  devices  not
ncorporated  into  the  CRT  device  are  dedicated  to  assess
irectly  the  pressure  in  the  pulmonary  artery  or  in  the  left
trium  [17,18].  However,  today,  there  is  no  strong  evidence
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that  the  monitoring  and  transmission  of  all  of  this  haemody-
namic  information  improves  the  outcome  of  non-responders.
Further  investigations  are  therefore  needed.
Conclusion
CRT  is  deﬁnitively  a  major  treatment  in  patients  with  LV
systolic  dysfunction,  wide  QRS  and  mild  to  severe  heart  fail-
ure  refractory  to  optimal  pharmacological  treatment,  but
the  proportion  of  non-responders  needs  to  be  reduced.  This
can  be  achieved  by  better  selection  of  candidates  but  also
by  improving  LV  lead  implantation.  The  future  should  also
conﬁrm  the  beneﬁt  of  CRT  in  different  populations,  such
as  patients  with  atrial  ﬁbrillation  or  requiring  permanent
right  ventricular  pacing.  Furthermore,  new  indications  are
of  potential  interest,  such  as  patients  with  a  narrow  QRS  and
patients  with  moderate  LV  systolic  dysfunction  (LV  ejection
fraction  >  35%).
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